Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettorre G, Plazzi M, Di Giambenedetto S, Antinori A. Zaccarelli M, et al. Among authors: di giambenedetto s. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19802. doi: 10.7448/IAS.17.4.19802. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397546 Free PMC article.
Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Zaccarelli M, Tozzi V, Ammassari A, Murri R, Antinori A. De Luca A, et al. Among authors: di giambenedetto s. AIDS. 2000 Jul 28;14(11):1655-6. doi: 10.1097/00002030-200007280-00022. AIDS. 2000. PMID: 10983653 No abstract available.
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, Antinori A. Zaccarelli M, et al. Among authors: di giambenedetto s. Antivir Ther. 2003 Feb;8(1):51-6. Antivir Ther. 2003. PMID: 12713064
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A. De Luca A, et al. Among authors: di giambenedetto s. J Infect Dis. 2003 Jun 15;187(12):1934-43. doi: 10.1086/375355. Epub 2003 May 22. J Infect Dis. 2003. PMID: 12792870 Clinical Trial.
Interpretation systems for genotypic drug resistance of HIV-1.
De Luca A, Antinori A, Di Giambenedetto S, Cingolani A, Colafigli M, Perno CF, Cauda R. De Luca A, et al. Among authors: di giambenedetto s. Scand J Infect Dis Suppl. 2003;106:29-34. doi: 10.1080/03008870310009623. Scand J Infect Dis Suppl. 2003. PMID: 15000579 Review.
302 results